Last reviewed · How we verify
NCT00305812
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Phase 2 trial testing dexamethasone in Multiple Myeloma and Plasma Cell Neoplasm in 51 participants. Completed in 30 June 2008.
30 June 2008
Quick facts
| Lead sponsor | NCIC Clinical Trials Group |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 51 |
| Start date | 9 March 2006 |
| Primary completion | 30 June 2008 |
| Estimated completion | 30 June 2008 |
| Sites | 14 locations across Canada |
Drugs / interventions tested
- dexamethasone (dexamethasone) — full drug profile →
- lenalidomide — full drug profile →
- melphalan (melphalan) — full drug profile →
Conditions studied
- Multiple Myeloma and Plasma Cell Neoplasm — all drugs for Multiple Myeloma and Plasma Cell Neoplasm →
Sponsor
NCIC Clinical Trials Group
Who can join
Adults 18 to 120, any sex, with Multiple Myeloma and Plasma Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with melphalan may kill more cancer cells. PURPOSE: This randomized phase II trial is studying the side effects and best dose of lenalidomide when given together with melphalan and to see how well they work in treating patients with multiple myeloma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00305812
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of dexamethasone
Trials testing the same drug.
- NCT06408974 — Comparison Between Ketamine Intrathecal and iv Dexamethasone for Post Cesarean Analgesia · Phase 4 · not yet recruiting
- NCT06508983 — A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in R · Phase 3 · recruiting
- NCT06120088 — U.S. Guided Erector Spinae Block for Postoperative Pain Management in Paraumbilical Hernia Repair Patients · unknown
- NCT06402149 — Comparison of 2 Different Methods in Infraclavicular Block · enrolling by invitation
- NCT04826237 — Oral Statins and Protection From Hearing Loss · Phase 4 · recruiting
Other recruiting trials for Multiple Myeloma and Plasma Cell Neoplasm
Currently open trials in the same condition.
- NCT00544115 — Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders · Phase 2 · active not recruiting
Other NCIC Clinical Trials Group trials
Trials by the same sponsor.
- NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
- NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
- NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
- NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
- NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00305812 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
- Last refreshed: 4 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00305812.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing